As mentioned previously, patients using SGLT2i had less severe AKI, and a previous study showed that AKI severity determined the risk of CKD progression.32 Furthermore, SGLT2i was shown to attenuate kidney capillary injury and fibrosis in an ischemic reperfusion injury mouse model through increased vascular endothelial growth factor expression.34 This evidence concerns the gene VEGFA and chronic kidney disease.